Pharmacology, Toxicology and Pharmaceutical Science
Cardiovascular Disease
100%
Sitagliptin
100%
Ertugliflozin
100%
Safety Assessment
100%
Hemoglobin A1c
75%
Human Papillomavirus Type 6
66%
C Peptide
50%
Homocysteine
50%
Atherosclerosis
40%
Uric Acid
25%
Ertugliflozin Plus Sitagliptin
25%
Cause of Death
20%
Diseases
20%
Cross-Validation
20%
Ischemic Heart Disease
20%
Obesity
20%
Condyloma acuminatum
16%
Uterine Cervix Dysplasia
16%
Mycosis
12%
Hypoglycemia
12%
Urinary Tract Infection
12%
Glycosylated Hemoglobin
12%
Progression Free Survival
12%
Sodium Glucose Cotransporter 2 Inhibitor
12%
Hypovolemia
12%
Medicine and Dentistry
Ertugliflozin
100%
Sitagliptin
100%
Patient with Type 2 Diabetes
100%
Human Papillomavirus Type 6
100%
Placebo
100%
Immunogenicity
100%
Genital Wart
46%
Atherosclerosis
40%
Ertugliflozin Plus Sitagliptin
25%
Anus Carcinoma
23%
Anal Cancer
23%
Sodium Retention
20%
Risk Stratification
20%
Sodium Glucose Cotransporter 2 Inhibitor
12%
Hypovolemia
12%
Glycemic Control
12%
Deltoid Muscle
7%
Anal Dysplasia
7%
Placebo-Controlled Study
7%
Intention-to-Treat Analysis
7%
Mathematics
Scale Model
100%
Statistical Prediction
100%
Survival Time
100%
Dempster-Shafer Theory
100%
Prediction Problem
33%
Unbiasedness
33%
Unbiased Predictor
33%
Decision Theory
33%
Transformation Group
25%
Decision Rule
25%
Statistical Decision Problem
25%